Literature DB >> 3499160

Pharmacokinetics of propofol in female patients. Studies using single bolus injections.

I D Cockshott1, L P Briggs, E J Douglas, M White.   

Abstract

The pharmacokinetics of propofol in a dose of 2.5 mg kg-1 given via a vein in the antecubital fossa were studied in 18 patients. Anaesthesia was maintained with nitrous oxide in oxygen in all patients. The effects of pretreatment with fentanyl (n = 6) and maintenance with halothane (n = 6) on the pharmacokinetics of propofol were also investigated. Pretreatment with fentanyl resulted in prolonged apnoea in four patients. No serious side effects occurred. The pharmacokinetics of propofol in unpretreated patients who were maintained with nitrous oxide in oxygen only can be described by a three-compartment open mammalian model with very rapid distribution (T1/2 alpha about 3 min), rapid elimination (T1/2 beta 45 min) and a slower final phase (T1/2 gamma about 300 min). The total body clearance of propofol was rapid (1.91 litre min-1). Propofol was initially distributed into a relatively large central compartment (41.3 litre) and was extensively redistributed (Vss 305 litre; V gamma 722 litre). Throughout the sampling period the mean blood concentrations of propofol for the patients pretreated with fentanyl were about 50% higher than the mean concentrations for patients maintained with nitrous oxide only. Mean propofol concentrations for the patients maintained with halothane were intermediate between those of the other two groups.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3499160     DOI: 10.1093/bja/59.9.1103

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  24 in total

Review 1.  Acute pancreatitis after single-dose exposure to propofol: a case report and review of literature.

Authors:  Qaiser Jawaid; Michael E Presti; Brent A Neuschwander-Tetri; Frank R Burton
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

Review 2.  Propofol: a sedative-hypnotic anesthetic agent for use in ambulatory procedures.

Authors:  D M Steinbacher
Journal:  Anesth Prog       Date:  2001

3.  Randomized comparison of outcome after propofol-nitrous oxide or enflurane-nitrous oxide anaesthesia in operations of long duration.

Authors:  K Korttila; P L Ostman; E Faure; J L Apfelbaum; M Ekdawi; M F Roizen
Journal:  Can J Anaesth       Date:  1989-11       Impact factor: 5.063

4.  Anesthetic properties of a propofol microemulsion in dogs.

Authors:  Timothy E Morey; Jerome H Modell; Dushyant Shekhawat; Dinesh O Shah; Brian Klatt; George P Thomas; Frank A Kero; Matthew M Booth; Donn M Dennis
Journal:  Anesth Analg       Date:  2006-10       Impact factor: 5.108

5.  Pharmacokinetics of propofol when given by intravenous infusion.

Authors:  D J Morgan; G A Campbell; D P Crankshaw
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

6.  Extended blood collection period required to define distribution and elimination kinetics of propofol.

Authors:  G A Campbell; D J Morgan; K Kumar; D P Crankshaw
Journal:  Br J Clin Pharmacol       Date:  1988-08       Impact factor: 4.335

7.  Thromboelastographic and pharmacokinetic profiles of micro- and macro-emulsions of propofol in swine.

Authors:  Timothy E Morey; Jerome H Modell; Jorge E Garcia; Michael Bewernitz; Hartmut Derendorf; Manoj Varshney; Nikolaus Gravenstein; Dinesh O Shah; Donn M Dennis
Journal:  Biopharm Drug Dispos       Date:  2010-07       Impact factor: 1.627

Review 8.  Propofol in patients with cardiac disease.

Authors:  N R Searle; P Sahab
Journal:  Can J Anaesth       Date:  1993-08       Impact factor: 5.063

9.  Quantifying the effect of isoflurane and nitrous oxide on somatosensory-evoked potentials.

Authors:  Usha Devadoss; S Babu; Vt Cherian
Journal:  Indian J Anaesth       Date:  2010-01

10.  Propofol sequestration within the extracorporeal circuit.

Authors:  M Hynynen; E Hammarén; P H Rosenberg
Journal:  Can J Anaesth       Date:  1994-07       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.